Antineoplastic effects of N-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: Preventive and therapeutic strategies

Nutrition and Cancer

Volumn 61, Issue 3, 2009, Pages 287-301

  Calviello, G ^a   Serini, S ^a   Piccioni, E ^a   Pessina, G ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF TUSCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE; BUTYRIC ACID; CAMPTOTHECIN; CELECOXIB; CLIOQUINOL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOCOSAHEXAENOIC ACID; DOXORUBICIN; EMODIN; EPIRUBICIN; FLUOROURACIL; GENISTEIN; HYDROXYCAMPTOTHECIN; ICOSAPENTAENOIC ACID; IMATINIB; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OMEGA 3 FATTY ACID; PACLITAXEL; PROTEIN BCL XL; TAMOXIFEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARACHIDONIC ACID METABOLISM; BREAST CANCER; BREAST CARCINOMA; CACHEXIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CELL MEMBRANE FLUIDITY; CHEMICAL CARCINOGENESIS; COLON ADENOCARCINOMA; COLON CANCER; COLON CARCINOGENESIS; DIET SUPPLEMENTATION; DRUG EFFICACY; ESOPHAGUS CANCER; FATTY ACID BLOOD LEVEL; GAMMA RADIATION; GENE OVEREXPRESSION; HIGH FIBER DIET; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE INJURY; LEUKEMIA; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; ONCOGENE NEU; OXIDATIVE STRESS; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; RISK REDUCTION; SARCOMA 180; T CELL LEUKEMIA; BREAST TUMOR; COLON TUMOR; DRUG EFFECT; FEMALE; LYMPHOMA; MALE; MEMBRANE FLUIDITY; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; ARACHIDONIC ACID; BREAST NEOPLASMS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; LEUKEMIA; LYMPHOMA; MALE; MEMBRANE FLUIDITY; NEOPLASMS; OXIDATIVE STRESS; PROSTATIC NEOPLASMS;

EID: 67649396491     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802582777     Document Type: Review

References (199)

1. Ruxton CH, Reed SC, Simpson MJ, and Millington KJ: The health benefits of omega-3 polyunsaturated fatty acids: A review of the evidence. J Hum Nutr Diet 20, 275-285, 2007.
2. Calviello G, Serini S, and Palozza P: N-3 polyunsaturated fatty acids as signal transduction modulators and therapeutical agents in cancer Current Signal Transduction Therapy 1, 255-271, 2006.
3. Reddy BS and Maruyama H: Effect of dietary fish oil on azoxymethaneinduced colon carcinogenesis in male F344 rats. Cancer Res 46, 3367-3370, 1986.
4. Calviello G, Palozza P, Piccioni E, MaggianoN, Frattucci A, et al.: Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: Effects on proliferation and apoptosis. Int J Cancer 75, 699-705, 1998.
5. Calviello G, Di Nicuolo F, Gragnoli S, Piccioni E, Serini S, et al.: N-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. Carcinogenesis 25, 2303-2310, 2004.
6. Petrik MB, McEntee MF, Johnson BT, Obukowicz MG, and Whelan J: Highly unsaturated (n-3) fatty acids, but not alpha-linolenic, conjugated linoleic or gamma-linolenic acids, reduce tumorigenesis in Apc(Min/+) mice. J Nutr 130, 2434-2443, 2000.
7. Chaj̀es V, Sattler W, Stranzl A, and Kostner GM: Influence of n-3 fatty acids on the growth of human breast cancer cells in vitro: Relationship to peroxides and vitamin-E. Breast Cancer Res Treat 34, 199-212, 1995.
8. Chamras H, Ardashian A, Heber D, and Glaspy JA: Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. J Nutr Biochem 13, 711-716, 2002.
9. Stoll BA: Linkage between retinoid and fatty acid receptors: Implications for breast cancer prevention. Eur J Cancer Prev 11, 319-325, 2002.
10. Calviello G, Di Nicuolo F, Serini S, Piccioni E, Boninsegna A, et al.: Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil. Cancer Chemother Pharmacol 55, 12-20, 2005.
11. Cha MC, Meckling KA, and Stewart C: Dietary docosahexaenoic acid levels influence the outcome of arabinosylcytosine chemotherapy in L1210 leukemic mice. Nutr Cancer 44, 176-181, 2002.
12. Lim K, Han C, Xu L, Isse K, Demetris AJ, et al.: Cyclooxygenase-2- derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: Evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res 68, 553-560, 2008.
13. Heukamp I, Kilian M, Gregor JI, Kiewert C, Schimke I, et al.: Impact of polyunsaturated fatty acids on hepato-pancreatic prostaglandin and leukotriene concentration in ductal pancreatic cancer-is there a correlation to tumour growth and liver metastasis? Prostaglandins Leukot Essent Fatty Acids 74, 223-233, 2006.
14. Trombetta A, Maggiora M, Martinasso G, Cotogni P, Canuto RA, et al.: Arachidonic and docosahexaenoic acids reduce the growth of A549 human lung-tumor cells increasing lipid peroxidation and PPARs. Chem Biol Interact 165, 239-250, 2007.
15. Anti M, Marra G, Armelao F, Bartoli GM, Ficarelli R, et al.: Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology 103, 883-891, 1992.
16. Anti M, Armelao F, Marra G, Percesepe A, Bartoli GM, et al.: Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas. Gastroenterology 107, 1709-1718, 1994.
17. Bartoli GM, Palozza P, Marra G, Armelao F, Franceschelli P, et al.: N- 3 PUFA and alpha-tocopherol control of tumor cell proliferation. Mol Aspects Med 14, 247-252, 1993.
18. Palozza P, Anti M, Franceschelli P, Marra G, Calviello G, et al.:Modulation of vitamin E level as a possible mechanism of the antiproliferative effect of n-3 PUFA. In: Oxygen paradox, Davies KJA (ed.).The University of Padova Press, Padova, Italy, 1995, pp. 653-664.
19. Huang YC, Jessup JM, Forse RA, Flickner S, Pleskow D, et al.: N-3 fatty acids decrease colonic epithelial cell proliferation in high-risk bowel mucosa. Lipids 31, S313-S317, 1996.
20. Cheng J, Ogawa K, Kuriki K, Yokoyama Y, Kamiya T, et al.: Increased intake of n-3 polyunsaturated fatty acids elevates the level of apoptosis in the normal sigmoid colon of patients polypectomized for adenomas/tumors. Cancer Lett 193, 17-24, 2003.
21. Polyunsaturated fatty acids treating patients with prostate cancer undergoing prostate biopsy and/or surgery. Dana Farber, Cancer Institute, NCT00458549. Retrieved October 2, 2008 from http://clinicaltrials.gov.
22. Colomer R, Moreno-Nogueira JM, Garć?a-Luna PP, Garć?a-Peris P, Garć?a-de-Lorenzo A, et al.: N-3 fatty acids, cancer and cachexia: A systematic review of the literature. Br J Nutr 97, 823-831, 2007.
23. BurnsCP, Halabi S,Clamon GH, HarsV,WagnerBA, et al.: Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: Cancer and leukemia group B study 9473. Clin Cancer Res 5, 3942-3947, 1999.
24. HardmanWE.: (n-3) fatty acids and cancer therapy. J Nutr 134(12Suppl), 3427S-3430S, 2004.
25. Terry PD, Terry JB, Rohan TE: Long-chain (n-3) fatty acid intake and risk of cancers of the breast and the prostate: Recent epidemiological studies, biological mechanisms, and directions for future research. J Nutr 134, 3412S-3420S, 2004.
26. Terry PD, Rohan TE, and Wolk A: Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormonerelated cancers: A review of the epidemiologic evidence. Am J Clin Nutr 77, 532-543, 2003.
27. Hites RA, Foran JA, Schwager SJ, Knuth BA, HamiltonMC, et al.: Global assessment of polybrominated diphenyl ethers in farmed and wild salmon. Environ Sci Technol 38, 4945-4949, 2004.
28. Chen ZY and Istfan NW: Docosahexaenoic acid, a major constituent of fish oil diets, prevents activation of cyclin-dependent kinases and S-phase entry by serum stimulation in HT-29 cells. Prostaglandins Leukot Essent Fatty Acids 64, 67-73, 2001.
29. Danbara N, Yuri T, Tsujita-Kyutoku M, Sato M, Senzaki H, et al.: Conjugated docosahexaenoic acid is a potent inducer of cell cycle arrest and apoptosis and inhibits growth of colo 201 human colon cancer cells. Nutr Cancer 50, 71-79, 2004.
30. Schonberg SA, Lundemo AG, Fladvad T, Holmgren K, Bremseth H, et al.: Closely related colon cancer cell lines display different sensitivity to polyunsaturated fatty acids, accumulate different lipid classes and downregulate sterol regulatory element-binding protein 1. FEBS J 273, 2749-2765, 2006.
31. Narayanan BA, Narayanan NK, and Reddy BS: Docosahexaenoic acid regulated genes and transcription factors inducing apoptosis in human colon cancer cells. Int J Oncol 19, 1255-1262, 2001.
32. Iigo M, Nakagawa T, Ishikawa C, Iwahori Y, Asamoto M, et al.: Inhibitory effects of docosahexaenoic acid on colon carcinoma 26 metastasis to the lung. Br J Cancer 75, 650-655, 1997.
33. Iwamoto S, Senzaki H, Kiyozuka Y, Ogura E, Takada H, et al.: Effects of fatty acids on liver metastasis of ACL-15 rat colon cancer cells.Nutr Cancer 31, 143-150, 1998.
34. Suzuki I, Iigo M, Ishikawa C, Kuhara T, Asamoto M, et al.: Inhibitory effects of oleic and docosahexaenoic acids on lung metastasis bycolon-carcinoma-26 cells are associated with reduced matrix metalloproteinase-2 and -9 activities. Int J Cancer 73, 607-612, 1997.
35. Reich R, Royce L, and Martin GR: Eicosapentaenoic acid reduces the invasive andmetastatic activities of malignant tumor cells. Biochem Biophys Res Commun 160, 559-564, 1989.
36. Mukutmoni-Norris M, Hubbard NE, and Erickson KL: Modulation of murine mammary tumor vasculature by dietary n-3 fatty acids in fish oil. Cancer Lett 150, 101-109, 2000.
37. Rose DP and Connolly JM: Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice. Int J Oncol 15, 1011-1015, 1999.
38. Brown TT, Zelnik DL, and Dobs AS: Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients. Int J Gastrointest Cancer 34, 143-150, 2003.
39. Chell S, Kaidi A, Williams AC, and Paraskeva C: Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 1766, 104-119, 2006.
40. Trifan OC and Hla T: Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 7, 207-222, 2003.
41. Ariel A and Serhan CN: Resolvins and protectins in the termination program of acute inflammation. Trends Immunol 28, 176-183, 2007.
42. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, et al.: Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J ExpMed 192, 1197-1204, 2000.
43. Arita M, Clish CB, and SerhanCN: The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: Novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem Biophys Res Commun 338, 149-157, 2005.
44. Sun YP, Oh SF, Uddin J, Yang R, Gotlinger K, et al.: Resolvin D1 and its aspirin-triggered 17R epimer: stereochemical assignments, antiinflammatory properties, and enzymatic inactivation. J Biol Chem 282, 9323-9334, 2007.
45. Mengeaud V, Nano JL, Fournel S, and Rampal P: Effects of eicosapentaenoic acid, gamma-linolenic acid and prostaglandin E1 on three human colon carcinoma cell lines. Prostaglandins Leukot Essent Fatty Acids 47, 313-319, 1992.
46. Ng Y, Barhoumi R, Tjalkens RB, Fan YY, Kolar S, et al.: The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. Carcinogenesis 26, 1914-1921, 2005.
47. Dommels YE, Haring MM, Keestra NG, Alink GM, van Bladeren PJ, et al.: The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines. Carcinogenesis 24, 385-392, 2003.
48. Maziere C, Conte MA, Degonville J, Ali D, and Maziere JC: Cellular enrichment with polyunsaturated fatty acids induces an oxidative stress and activates the transcription factors AP1 and NFkappaB. Biochem Biophys Res Commun 265, 116-122, 1999.
49. Bubici C, Papa S, Dean K, and Franzoso G: Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: Molecular basis and biological significance. Oncogene 25, 6731-6748, 2006.
50. Simon HU, Haj-Yehia A, and Levi-Schaffer F: Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5, 415-418, 2000.
51. Hofmanova J,Vaculova A, Lojek A, andKozub̀?k A: Interaction of polyunsaturated fatty acids and sodium butyrate during apoptosis inHT-29 human colon adenocarcinoma cells. Eur J Nutr 44, 40-51, 2005. (Pubitemid 40254234)
52. Komatsu W, Ishihara K, Murata M, Saito H, and Shinohara K: Docosahexaenoic acid suppresses nitric oxide production and inducible nitric oxide synthase expression in interferon-gamma plus lipopolysaccharidestimulated murine macrophages by inhibiting the oxidative stress. Free Radic Biol Med 34, 1006-1016, 2003.
53. Sneddon AA,Wu HC, Farquharson A, Grant I,Arthur JR, et al.:Regulation of selenoprotein GPx4 expression and activity in human endothelial cells by fatty acids, cytokines and antioxidants. Atherosclerosis 171, 57-65, 2003.
54. Sarsilmaz M, Songur A, Ozyurt H, Kus I, Ozen OA, et al.: Potential role of dietary omega-3 essential fatty acids on some oxidant/antioxidant parameters in rats' corpus striatum. Prostaglandins Leukot Essent Fatty Acids 69, 253-259, 2003.
55. Treen M, Uauy RD, Jameson DM, Thomas VL, and Hoffman DR: Effect of docosahexaenoic acid on membrane fluidity and function in intact cultured Y-79 retinoblastoma cells. Arch Biochem Biophys 294, 564-570, 1992.
56. Meuillet EJ, Wiernsperger N, Mania-Farnell B, Hubert P, and Cremel G: Metforminmodulates insulin receptor signaling in normal and cholesteroltreated human hepatoma cells (HepG2). Eur J Pharmacol 377, 241-252, 1999.
57. Valentine RC and Valentine DL: Omega-3 fatty acids in cellular membranes: A unified concept. Prog Lipid Res 43, 383-402, 2004.
58. Zerouga M, Jenski LJ, Booster S, and Stillwell W: Can docosahexaenoic acid inhibit metastasis by decreasing deformability of the tumor cell plasma membrane? Cancer Lett 119, 163-168, 1997.
59. Stillwell W, Ehringer W, and Jenski LJ: Docosahexaenoic acid increases permeability of lipid vesicles and tumor cells. Lipids 28, 103-108, 1993.
60. Pascale AW, Ehringer WD, Stillwell W, Sturdevant LK, and Jenski LJ: Omega-3 fatty acid modification of membrane structure and function: II. alteration by docosahexaenoic acid of tumor cell sensitivity to immune cytolysis. Nutr Cancer 19, 147-157, 1993. (Pubitemid 23131432)
61. Williams EE, Jenski LJ, and Stillwell W: Docosahexaenoic acid (DHA) alters the structure and composition of membranous vesicles exfoliated from the surface of a murine leukemia cell line. Biochim Biophys Acta 1371, 351-362, 1998.
62. StillwellWandWassall SR: Docosahexaenoic acid: Membrane properties of a unique fatty acid. Chem Phys Lipids 126, 1-27, 2003.
63. Ma DW, Seo J, Switzer KC, Fan YY, McMurray DN, et al.: N-3 PUFA and membrane microdomains: A new frontier in bioactive lipid research. J Nutr 15, 700-706, 2004.
64. Chapkin RS,Wang N, Fan YY, Lupton JR, and Prior IA: Docosahexaenoic acid alters the size and distribution of cell surface microdomains. Biochim Biophys Acta 1778, 466-471, 2008.
65. London E: Insights into lipid raft structure and formation from experiments in model membranes. Curr Opin Struct Biol 12, 480-486, 2002.
66. Li Q,Wang M, Tan L,Wang C,Ma J, et al.: Docosahexaenoic acid changes lipid composition and interleukin-2 receptor signaling in membrane rafts. J Lipid Res 46, 1904-1913, 2005.
67. Li Q, ZhangQ,WangM,Liu F, Zhao S, et al.:Docosahexaenoic acid affects endothelial nitric oxide synthase in caveolae. Arch Biochem Biophys 466, 250-259, 2007.
68. Li Q, Zhang Q,WangM, Zhao S,Ma J, et al.: Eicosapentaenoic acid modifies lipid composition in caveolae and induces translocation of endothelial nitric oxide synthase. Biochimie 89, 169-177, 2007.
69. Chen W, Jump DB, Esselman WJ, and Busik JV: Inhibition of cytokine signaling in human retinal endothelial cells through modification of caveolae/ lipid rafts by docosahexaenoic acid. Invest Ophthalmol Vis Sci 48, 18-26, 2007.
70. Ross JA, Maingay JP, Fearon KC, Sangster K, and Powell JJ: Eicosapentaenoic acid perturbs signalling via the NFkappaB transcriptional pathway in pancreatic tumour cells. Int J Oncol 23, 1733-1738, 2003.
71. Liu G, Bibus DM, Bode AM,MaWY, Holman RT, et al.: Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells. Ann NY Acad Sci USA 98, 7510-7515, 2001.
72. Kinser S, Li M, Jia Q, and Pestka JJ: Truncated deoxynivalenol-induced splenic immediate early gene response in mice consuming (n-3) polyunsaturated fatty acids. J Nutr Biochem 16, 88-95, 2005.
73. Finstad HS,Kolset SO, Holme JA,WigerR, Farrants AK, et al.: Effect of n- 3 and n-6 fatty acids on proliferation and differentiation of promyelocytic leukemic HL-60 cells. Blood 84, 3799-3809, 1994.
74. Kim HJ, Vosseler CA, Weber PC, and Erl W: Docosahexaenoic acid induces apoptosis in proliferating human endothelial cells. J Cell Physiol 204, 881-888, 2005.
75. Zand H, Rhimipour A, Bakhshayesh M, Shafiee M, Nour Mohammadi I, et al.: Involvement of PPAR-gamma and p53 in DHA-induced apoptosis in Reh cells. Mol Cell Biochem 304, 71-77, 2007.
76. Komatsu W, Ishihara K, Murata M, Saito H, and Shinohara K: Docosahexaenoic acid suppresses nitric oxide production and inducible nitric oxide synthase expression in interferon-gamma plus lipopolysaccharidestimulated murine macrophages by inhibiting the oxidative stress. Free Radic Biol Med 34, 1006-1016, 2003.
77. Joshi-Barve S, Barve S, and Chen LH: Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr 23, 71-78, 2004.
78. Narayanan BA, Narayanan NK, Simi B, and Reddy BS: Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer Res 63, 972-979, 2003.
79. Narayanan BA, Narayanan NK, Desai D, Pittman B, and Reddy BS: Effects of a combination of docosahexaenoic acid and 1,4-phenylene bis(methylene) selenocyanate on cyclooxygenase 2, inducible nitric oxide synthase and beta-catenin pathways in colon cancer cells. Carcinogenesis 25, 2443-2449, 2004.
80. Weldon SM, Mullen AC, Loscher CE, Hurley LA, and Roche HM: Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem 18, 250-258, 2007.
81. Dolcet X, Llobet D, Pallares J, andMatias-Guiu X: NF-kB in development and progression of human cancer. Virchows Arch 446, 475-482, 2005.
82. Narayanan NK, Narayanan BA, and Reddy BS: A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors. Int J Oncol 26, 785-792, 2005.
83. Schley PD, Jijon HB, Robinson LE, and Field CJ:Mechanisms of omega- 3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 92, 187-195, 2005.
84. Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23, 2838-2849, 2004.
85. Collett ED, Davidson LA, Fan YY, Lupton JR, and Chapkin RS: N-6 and n-3 polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am J Physiol Cell Physiol 280, C1066-C1075, 2001.
86. Yusufi AN, Cheng J, Thompson MA, Walker HJ, Gray CE, et al.: Differential effects of low-dose docosahexaenoic acid and eicosapentaenoic acid on the regulation of mitogenic signaling pathways in mesangial cells. J Lab Clin Med 141, 318-329, 2003.
87. MoonYand Pestka JJ: Deoxynivalenol-induced mitogen-activated protein kinase phosphorylation and IL-6 expression in mice suppressed by fish oil. J Nutr Biochem 14, 717-726, 2003.
88. Diep QN, Touyz RM, and Schiffrin EL: Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension 36, 851-855, 2000.
89. Xue H, Wan M, Song D, Li Y, Li J: Eicosapentaenoic acid and docosahexaenoic acid modulate mitogen-activated protein kinase activity in endothelium. Vascul Pharmacol 44, 434-439, 2006.
90. Jia Q, Zhou HR, Bennink M, and Pestka JJ: Docosahexaenoic acid attenuates mycotoxin-induced immunoglobulin a nephropathy, interleukin-6 transcription, and mitogen-activated protein kinase phosphorylation in mice. J Nutr 134, 3343-3349, 2004.
91. Schaefer MB, Wenzel A, Fischer T, Braun-Dullaeus RC, Renner F, et al.: Fatty acids differentially influence phosphatidylinositol 3-kinase signal transduction in endothelial cells: Impact on adhesion and apoptosis. Atherosclerosis 197, 630-637, 2007.
92. Aires V, Hichami A, Filomenko R, Pĺe A, Ŕeb́e C, et al.: Docosahexaenoic acid induces increases in [Ca2+]i via inositol 1,4,5-triphosphate production and activates protein kinase C gamma and -delta via phosphatidylserine binding site: Implication in apoptosis in U937 cells. Mol Pharmacol 72, 1545-1556, 2007.
93. Serini S, Trombino S, Oliva F, Piccioni E, Monego G, et al.: Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP- 1 and down-regulating p-ERK1/2 and p-p38 expression. Apoptosis 13, 1172-1183, 2008.
94. Siddiqui RA, Jenski LJ, Harvey KA,Wiesehan JD, StillwellW, et al.: Cellcycle arrest in Jurkat leukaemic cells: A possible role for docosahexaenoic acid. Biochem J 371, 621-962, 2003.
95. Siddiqui RA, Jenski LJ, Neff K, Harvey K, Kovacs RJ, et al.: Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein phosphatasemediated process. Biochim Biophys Acta 1499, 265-275, 2001.
96. Llor X, Pons E, Roca A, Alvarez M, Mãńe J, et al.: The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes. Clin Nutr 22, 71-79, 2003.
97. Arita K, Kobuchi H, Utsumi T, Takehara Y, Akiyama J, et al.: Mechanism of apoptosis in HL-60 cells induced by n-3 and n-6 polyunsaturated fatty acids. Biochem Pharmacol 62, 821-828, 2001.
98. Heimli H, Giske C, Naderi S, Drevon CA, and Hollung K: Eicosapentaenoic acid promotes apoptosis in Ramos cells via activation of caspase-3 and -9. Lipids 37, 797-802, 2002.
99. Wu M, Harvey KA, Ruzmetov N, Welch ZR, Sech L, et al.: Omega-3 polyunsaturated fatty acids attenuate breast cancer growth through activation of a neutral sphingomyelinase-mediated pathway. Int J Cancer 117, 340-348, 2005.
100. Roberfroid MB: Dietary modulation of experimental neoplastic development: Role of fat and fiber content and calorie intake. Mutat Res 259, 351-362, 1991.
101. Reddy BS: Nutritional factors and colon cancer. Crit Rev Food Sci Nutr 35, 175-190, 1995.
102. Dupertuis YM, Meguid MM, and Pichard C: Colon cancer therapy: New perspectives of nutritional manipulations using polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 10, 427-432, 2007.
103. Calviello G, Serini S, and Piccioni E: N-3 polyunsaturated fatty acids and the prevention of colorectal cancer: Molecular mechanisms involved. Curr Med Chem 14, 3059-3069, 2007.
104. Wynter MP, Russell ST, and Tisdale MJ: Effect of n-3 fatty acids on the antitumour effects of cytotoxic drugs. In Vivo 18, 543-547, 2004.
105. Ǵomez de Segura IA, Valderŕabano S, V́azquez I, Vallejo-Cremades MT, Ǵomez-Garć?a L, et al.: Protective effects of dietary enrichment with docosahexaenoic acid plus protein in 5-fluorouracil-induced intestinal injury in the rat. Eur J Gastroenterol Hepatol 16, 479-485, 2004.
106. Jordan A and Stein J: Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2. Eur J Nutr 42, 324-331, 2003.
107. Askew DS, Ashmun RA, Simmons BC, and Cleveland JL: Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6, 1915-1922, 1991.
108. Arango D, Corner GA, Wadler S, Catalano PJ, and Augenlicht LH: Cmyc/ p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 61, 4910-4915, 2001.
109. Vaculov́a A, Hofmanov́a J, Andera L, and Kozub́?k A: TRAIL and docosahexaenoic acid cooperate to induce HT-29 colon cancer cell death. Cancer Lett 229, 43-48, 2005.
110. Nagane M, Huang HJ, and Cavenee WK: The potential of TRAIL for cancer chemotherapy. Apoptosis 6, 191-197, 2001.
111. Kim K, Fisher MJ, Xu SQ, and el-Deiry WS: Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6, 335-346, 2000.
112. Cha MC, Lin A, and Meckling KA: Low dose docosahexaenoic acid protects normal colonic epithelial cells from araC toxicity. BMC Pharmacol 5, 7-14, 2005.
113. Gandhi V, Estey E, and Plunkett W: Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol 370, 119-124, 1994.
114. Grem JL, Geoffroy F, Politi PM, Cuddy DP, Ross DD, et al.: Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells. Mol Pharmacol 48, 305-315, 1995.
115. Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, et al.: Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 47, 839-852, 1994.
116. Denys A, Hichami A, Maume B, and Khan NA: Docosahexaenoic acid modulates phorbol ester-induced activation of extracellular signalregulated kinases 1 and 2 in NIH/3T3 cells. Lipids 36, 813-818, 2001.
117. PadmaMand Das UN: Effect of cis-unsaturated fatty acids on the activity of protein kinases and protein phosphorylation inmacrophage tumor (AK- 5) cells in vitro. Prostaglandins Leukot Essent Fatty Acids 60, 55-63, 1999.
118. Davidson LA, Brown RE, Chang WC,Morris JS,Wang N, et al.: Morphodensitometric analysis of protein kinase C beta(II) expression in rat colon: Modulation by diet and relation to in situ cell proliferation and apoptosis. Carcinogenesis 21, 1512-1519, 2000.
119. Lupton JR: Microbial degradation products influence colon cancer risk: The butyrate controversy. J Nutr 134, 479-482, 2004.
120. Bingham SA, DayNE, LubenR, Ferrari P, SlimaniN, et al.:Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): An observational study. Lancet 361, 1496-1501, 2003.
121. Chapkin RS, Seo J,McMurray DN, and Lupton JR:Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine. Chem Phys Lipids 153, 14-23, 2008.
122. Chang WL, Chapkin RS, and Lupton JR: Fish oil blocks azoxymethaneinduced rat colon tumorigenesis by increasing cell differentiation and apoptosis rather than decreasing cell proliferation. J Nutr 128, 491-497, 1998.
123. Kolar SS, Barhoumi R, Lupton JR, and Chapkin RS.: Docosahexaenoic acid and butyrate synergistically induce colonocyte apoptosis by enhancing mitochondrial Ca2+ accumulation. Cancer Res 67, 5561-5568, 2007. (Pubitemid 46997299)
124. Chapkin RS, HongMY, FanYY,Davidson LA, Sanders LM, et al.:Dietary n-3 PUFA alter colonocyte mitochondrial membrane composition and function. Lipids 37, 193-199, 2002.
125. Hong MY, Chapkin RS, Barhoumi R, Burghardt RC, Turner ND, et al.: Fish oil increases mitochondrial phospholipid unsaturation, upregulating reactive oxygen species and apoptosis in rat colonocytes. Carcinogenesis 23, 1919-1925, 2002.
126. Ng Y, Barhoumi R, Tjalkens RB, Fan YY, Kolar S, et al.: The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. Carcinogenesis 26, 1914-1921, 2005.
127. Fan YY, Zhang J, Barhoumi R, Burghardt RC, Turner ND, et al.: Antagonism of CD95 signaling blocks butyrate induction of apoptosis in young adult mouse colonic cells. Am J Physiol 277, C310-C319, 1999.
128. Vanamala J, Glagolenko A, Yang P, Carroll RJ, Murphy ME, et al.: Dietary fish oil and pectin enhance colonocyte apoptosis in part through suppression of PPARdelta/PGE2 and elevation of PGE3. Carcinogenesis 29, 790-796, 2008.
129. SinhaBKandMimnaugh EG: Free radicals and anticancer drug resistance: Oxygen free radicals in themechanisms of drug cytotoxicity and resistance by certain tumors. Free Radic Biol Med 8, 567-581, 1990.
130. Germain E, Chaj̀es V, Cognault S, Lhuillery C, and Bougnoux P: Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: Relationship to lipid peroxidation. Int J Cancer 75, 578-583, 1998.
131. Hardman WE, Avula CP, Fernandes G, and Cameron IL: Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clin Cancer Res 7, 2041-2049, 2001.
132. Mah́eo K, Vibet S, Steghens JP, Dartigeas C, Lehman M, et al.: Differential sensitization of cancer cells to doxorubicin by DHA: A role for lipoperoxidation. Free Radic Biol Med 39, 742-751, 2005.
133. Vibet S, Goupille C, Bougnoux P, Steghens JP, Goŕe J, et al.: Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med 44, 1483-1491, 2008.
134. Colas S, Mah́eo K, Denis F, Goupille C, Hoinard C, et al.: Sensitization by dietary docosahexaenoic acid of ratmammary carcinoma to anthracycline: A role for tumor vascularization. Clin Cancer Res 12, 5879-5886, 2006.
135. Calviello G, Di Nicuolo F, Gragnoli S, Piccioni E, Serini S, et al.: N-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. Carcinogenesis 25, 2303-2310, 2004.
136. Kase Y, Hayakawa T, Togashi Y, and Kamataki T: Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats. Jpn J Pharmacol 75, 399-405, 1997. (Pubitemid 28020073)
137. Sakai H, Sato T, Hamada N, Yasue M, Ikari A, et al.: Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Clsecretion in isolated rat colon. J Physiol 505, 133-144, 1997.
138. Menendez JA, Lupu R, Cand olomer R: Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n- 3) synergistically enhances taxane cytotoxicity and downregulates Her- 2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur J Cancer Prev 14, 263-270, 2005.
139. Menendez JA, Ropero S, Lupu R, and Colomer R: Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Oncol Rep 11, 1241-1252, 2004.
140. deGraffenried LA, FriedrichsWE, Russell DH, Donzis EJ,Middleton AK, et al.: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10, 8059-8067, 2004.
141. Clark AS,West K, Streicher S, and Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1, 707-717, 2002.
142. Seeger H, Wallwiener D, and Mueck AO: Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 111, 47-48, 2003.
143. Alonso DF, Farina HG, Skilton G, Gabri MR, de Lorenzo MS, et al.: Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50, 83-93, 1998.
144. Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, et al.: Lipid-lowering drug use and breast cancer in older women: A prospective study. J Women's Health 12, 749-756, 2003.
145. Chan KK, Oza AM, and Siu LL: The statins as anticancer agents. Clin Cancer Res 9, 10-19, 2003.
146. El-Sohemy A and Archer MC: Regulation of mevalonate synthesis in rat mammary glands by dietary n-3 and n-6 polyunsaturated fatty acids. Cancer Res 57, 3685-3687, 1997.
147. Duncan RE, El-Sohemy A, and Archer MC: Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin. Cancer Lett 224, 221-228, 2005.
148. Siddiqui RA, Zerouga M, Wu M, Castillo A, Harvey K, et al.: Anticancer poperties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells. Breast Cancer Res 7, R645-R654, 2005.
149. Bougnoux P, Hajjaji N, BaucherMA, JourdanML, Goupille C, et al.: Docosahexaenoic acid (DHA) intake during first line chemotherapy improve survival in metastatic breast cancer. Proc Am Assoc Cancer Res 47, 5276, 2006 (abstr.).
150. Horia E and Watkins BA: Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis 28, 809-815, 2007.
151. Rowell C, Carpenter DM, and Lamartiniere CA: Chemoprevention of breast cancer, proteomic discovery of genistein action in the rat mammary gland. J Nutr 135, 2953S-2959S, 2005.
152. Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, and Jackson RT: Prostate cancer risk and consumption of fish oils: A dietary biomarker-based casecontrol study. Br J Cancer 81, 1238-1242, 1999.
153. Dewailly E, Mulvad G, Sloth Pedersen H, Hansen JC, Behrendt N, et al.: Inuit are protected against prostate cancer. Cancer Epidemiol Biomarkers Prev 12, 926-927, 2003.
154. Chung BH, Mitchell SH, Zhang JS, and Young CY: Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis 22, 1201-1206, 2001.
155. Rose DP and Cohen LA: Effects of dietary menhaden oil and retinyl acetate on the growth of DU 145 human prostatic adenocarcinoma cells transplanted into athymic nude mice. Carcinogenesis, 9, 603-605, 1988.
156. Narayanan NK, Narayanan BA, Bosland M, Condon MS, and Nargi D: Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. Int J Cancer 119, 1586-1598, 2006.
157. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, et al.: Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2- independent mechanism. Clin Cancer Res 11, 1999-2007, 2005.
158. Gambaro G and Perazella MA: Adverse renal effects of anti-inflammatory agents: Evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 253, 643-652, 2003.
159. Fosslien E: Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 28, 67-81, 1998.
160. Anel A, Naval J, Desportes P, Gonźalez B, and Uriel J: Increased cytotoxicity of polyunsaturated fatty acids on human tumoral B and T-cell lines compared with normal lymphocytes. Leukemia 6, 680-688, 1992.
161. Miura Y, Takahara K, Murata Y, Utsumi K, Tada M, et al.: Docosahexaenoic acid induces apoptosis via the Bax-independent pathway in HL-60 cells. Biosci Biotechnol Biochem 68, 2415-2417, 2004.
162. Chiu LC,Wong EY, and Ooi VE: Docosahexaenoic acid modulates different genes in cell cycle and apoptosis to control growth of human leukemia HL-60 cells. Int J Oncol 25, 737-744, 2004.
163. Cha MC, Meckling KA, and Stewart C: Dietary docosahexaenoic acid levels influence the outcome of arabinosylcytosine chemotherapy in L1210 leukemic mice. Nutr Cancer 44, 176-181, 2002.
164. Guffy MM, North JA, and Burns CP: Effect of cellular fatty acid alteration on adriamycin sensitivity in cultured L1210 murine leukemia cells. Cancer Res 44, 1863-1866, 1984.
165. Dalmark Mand and Storm HH: A fickian diffusion transport process with features of transport catalysis. J Gen Physiol 78, 349-364, 1981.
166. de Salis HM and Meckling-Gill KA: EPA and DHA alter nucleoside drug and doxorubicin toxicity in L1210 cells but not in normal murine S1 macrophages. Cell Pharmacol 2, 69-74, 1995.
167. Cha MC and Meckling-Gill KA: Modifications of deoxycytidine kinase and deaminase activities by docosahexaenoic acid in normal and transformed rat fibroblasts. Biochem Pharmocol 63, 717-723, 2002.
168. Wang Y, Li L, Jiang W, Yang Z, and Zhang Z: Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate. Bioorg Med Chem Lett 16, 2974-2977, 2006.
169. Kinsella JE and Black JM: Effects of polyunsaturated fatty acids on the efficacy of antineoplastic agents toward L5178Y lymphoma cells. Biochem Pharmacol 45, 1881-1887, 1993.
170. Sturlan S, Baumgartner M, Roth E, and Bachleitner-Hofmann T: Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood 101, 4990-4997, 2003.
171. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, et al.: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89, 3345-3353, 1997.
172. Hermine O, Dombret H, Poupon J, Arnulf B, Lefr̀ere F, et al.: Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/ refractory adult T-cell leukemia/lymphoma. Hematol J 5, 130-134, 2004.
173. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, et al.: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88, 1052-1061, 1996.
174. Yeh SF, Chou TC, and Liu TS: Effects of anthraquinones of Polygonum cuspidatum on HL-60 cells. Planta Medica 54, 413-414, 1988.
175. BrownM, BellonM, and Nicot C: Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood 109, 1653-1659, 2007.
176. Mantadakis E, Cole PD, and Kamen BA: High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use? Pharmacotherapy 25, 748-755, 2005.
177. ZerougaM, StillwellW, and Jenski LJ: Synthesis of a novel phosphatidylcholine conjugated to docosahexaenoic acid andmethotrexate that inhibits cell proliferation. Anticancer Drugs 13, 301-311, 2002.
178. de Lima TM, Amarante-Mendes GP, and Curi R: Docosahexaenoic acid enhances the toxic effect of imatinib on Bcr-Abl expressing HL-60 cells. Toxicol In Vitro 21, 1678-1685, 2007.
179. Martinelli G, Soverini S, Rosti G, Cilloni D, and Baccarani M: New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica 90, 534-541, 2005. (Pubitemid 40592897)
180. Mi Z, Malak H, and Burke TG: Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 34, 13722-13728, 1995.
181. Wang Y, Li L, Jiang W, and Larrick JW: Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate. Bioorg Med Chem 13, 5592-5599, 2005.
182. Lindskog M, Gleissman H, Ponthan F, Castro J, Kogner P, et al.: Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int J Cancer 118, 2584-2593, 2006.
183. BaumgartnerM, Sturlan S, Roth E,Wessner B, and Bachleitner-Hofmann T: Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int J Cancer 112, 707-712, 2004.
184. Chiu LC, Tong KF, and Ooi VE: Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanomaA-375 cells. E Biomed Pharmacother 59, S293-S297, 2005.
185. Ikushima S, Fujiwara F, Todo S, and Imashuku S: Effects of polyunsaturated fatty acids on vincristine-resistance in human neuroblastoma cells. Anticancer Res 11, 1215-1220, 1991.
186. Ding WQ, Liu B, Vaught JL, Palmiter RD, and Lind SE: Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol Cancer Ther 5, 1864-1872, 2006.
187. Kimura Y, Takaku T, Nakajima S, and Okuda H: Effects of carp and tuna oils on 5-fluorouracil-induced antitumor activity and side effects in sarcoma 180-bearing mice. Lipids 36, 353-359, 2001.
188. BradleyMO,Webb NL, Anthony FH, Devanesan P,Witman PA, et al.: Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 7, 3229-3238, 2001.
189. Sauer LA and Dauchy RT: The effect of omega-6 and omega-3 fatty acids on 3H-thymidine incorporation in hepatoma 7288CTC perfused in situ. Brit J Cancer 66, 297-303, 1992.
190. Payne M, Ellis P, Dunlop D, Ranson M, Danson S, et al.: DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV nonsmall cell lung cancer: Report of a phase II open-label multicenter trial. Thorac Oncol 1, 984-990, 2006.
191. Jones RJ, Hawkins RE, Eatock MM, Ferry DR, Eskens FA, et al.: A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol 61, 435-441, 2008.
192. Vartak S, Robbins ME, and Spector AA: Polyunsaturated fatty acids increase the sensitivity of 36B10 rat astrocytoma cells to radiation-induced cell kill. Lipids 32, 283-292, 1997.
193. Zand H, Rahimipour A, Salimi S, and Shafiee SM: Docosahexaenoic acid sensitizes Ramos cells to gamma-irradiation-induced apoptosis through involvement of PPAR-gamma activation and NF-kappaB suppression. Mol Cell Biochem 317, 113-120, 2008.
194. Colas S, Paon L, Denis F, Prat M, Louisot P, et al.: Enhanced radiosensitivity of rat autochthonous mammary tumors by dietary docosahexaenoic acid. Int J Cancer 109, 449-454, 2004.
195. Wen B, Deutsch E, Opolon P, Auperin A, Frascogna V, et al.: N-3 polyunsaturated fatty acids decrease mucosal/epidermal reactions and enhance antitumour effect of ionising radiation with inhibition of tumour angiogenesis. Br J Cancer 89, 1102-1107, 2003.
196. Minami Y, Miyata H, Doki Y, Yano M, Yamasaki M, et al.: Omega-3 Fatty acid-containing diet (Racol) reduces toxicity of chemoradiation therapy for patients with esophageal cancer. Gan To Kagaku Ryoho 35, 437-440, 2008.
197. Sijtsma L and De Swaaf ME: Biotechnological production and applications of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. Appl Microbiol Biotechnol 64, 146-153, 2004.
198. PulzOand GrossW:Valuable products from biotechnology of microalgae. Appl Microbiol Biotechnol 65, 635-648, 2004.
199. Calviello G, Serini S, Piccioni E, Rinaldi C, Mostra D, et al.: Fish species living in an artificial lake with high quality waters a san optimal source of n-3 PUFAs. 8th Meeting of the International Society for the Study of Fatty Acids and Lipids (ISSFAL), Kansas City, Missouri, 2008. Retrieved October 2, 2008 from http://www.issfal.org.uk/index. php?option=com content&task= view&id=141&Itemid=182 (abstr.).